Companies
/Healthcare
Neumora Therapeutics Inc
$0.38
▼ $0.03 (−6.48%) today
Markets closed · 4:01am ET
NMRA at a Glance
Valuation
- Market cap
- $76.2M
Profitability
- EPS (TTM)
- $-1.21
Price
- 52-week range
- $0 – $4
- Street target
- $6.14
Earnings
- Next report
- Nov 5, 2026
Headquartered in Watertown, MA Fiscal year ends December NASDAQ: NMRA neumoratx.com
About Neumora Therapeutics
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain and centrally mediated diseases. The company's therapeutic pipeline targets novel mechanisms of action for underserved, prevalent conditions including Alzheimer's disease agitation, schizophrenia, obesity, and cardiometabolic disease. Key pipeline candidates include NMRA-215 (an NLRP3 inhibitor for obesity and cardiometabolic disease), NMRA-511 (a vasopressin 1a receptor antagonist for Alzheimer's disease agitation), and NMRA-898 (an M4 positive allosteric modulator for schizophrenia). The company is pre-revenue and trades on Nasdaq under the ticker NMRA. Updated
Frequently Asked Questions
What does Neumora Therapeutics do?
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain and centrally mediated diseases.
What is the NMRA stock price target?
The Wall Street consensus 12-month price target for NMRA is $6.14.